Related Experiment Video
Updated: Apr 16, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Detection of EGFR-TK domain-activating mutations in NSCLC with generic PCR-based methods
Rajendra B Shahi1, Sylvia De Brakeleer, Jacques De Grève
1*Department of Medical Oncology and Laboratory of Medical and Molecular Oncology, Oncologisch Centrum †Department of Pathology, UZ-Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
Detecting epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) is crucial for targeted therapy. A sensitive PCR-DGGE method effectively identified EGFR mutations in limited clinical samples, with enhanced detection using peptide nucleic acid probes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Somatic mutations in the epidermal growth factor receptor-tyrosine kinase (EGFR-TK) domain are key predictors of non-small cell lung cancer (NSCLC) response to EGFR-TK inhibitors.
- Clinical samples from NSCLC patients are often limited, poorly preserved, and contain a mix of normal and tumor cells, complicating mutation analysis.
- Limited DNA quantity and underrepresented mutant alleles necessitate highly sensitive detection methods for accurate EGFR mutation screening.
Purpose of the Study:
- To evaluate the sensitivity and effectiveness of a heminested polymerase chain reaction (PCR) followed by denaturing gradient gel electrophoresis (DGGE) assay for detecting EGFR-TK domain mutations in NSCLC.
- To assess the utility of peptide nucleic acid (PNA) probes in enhancing the sensitivity of mutation detection, particularly for low-frequency alleles.
Main Methods:
- EGFR mutation screening was performed on 210 NSCLC samples using heminested PCR and DGGE, followed by sequencing for mutation characterization.
- Samples initially negative for mutations (149 cases) were reanalyzed using real-time PCR with PNA probes for enhanced detection of specific exon 19 and 21 mutations.
Main Results:
- The PCR-DGGE assay identified 17 different pathogenic EGFR-TK domain mutations in 55 out of 210 samples (26%).
- The assay demonstrated high sensitivity, detecting mutations in samples with as low as 10% tumor cell content.
- An additional four samples with exon 19 mutations were detected after reanalysis with real-time PCR and PNA probes, increasing the overall detection rate.
Conclusions:
- The PCR-DGGE assay is a sensitive and cost-effective method for detecting EGFR mutations in challenging clinical NSCLC samples.
- The integration of PNA probes can further improve the sensitivity and speed of mutation detection for specific EGFR mutations, especially in low tumor cellularity samples.
- These findings underscore the importance of sensitive molecular diagnostics for personalized treatment strategies in NSCLC.
